EGFR and glioblastoma: Interestingly, using 150 patients who had NGS of 315 gene panel, we observed that 87% had mutations of all 3 canonical pathways (RTK/PI3K, p53, and Rb), so EGFR amplification may be just one of many mechanisms for GBM tumorigenesis and thus may not carry any prognostic impact.